These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37905183)

  • 1. Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States.
    Coleman RL; Garside J; Hurteau J; Nguyen J; Kobayashi M
    J Health Econ Outcomes Res; 2023; 10(2):82-90. PubMed ID: 37905183
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
    Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
    Roset M; Amonkar M; Patel R; Lara N; Kothari S
    Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
    Heffernan K; Nikitas FS; Shukla U; Camejo HS; Knott C
    Gynecol Oncol; 2022 Aug; 166(2):317-325. PubMed ID: 35752507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States.
    Liu J; Emond B; Maiese EM; Lafeuille MH; Lefebvre P; Ghelerter I; Wu C; Hurteau JA; Thaker PH
    Curr Med Res Opin; 2022 Nov; 38(11):1935-1945. PubMed ID: 35975577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States.
    Kelkar SS; Prabhu VS; Zhang J; Corman S; Macahilig C; Rusibamayila N; Odak S; Duska LR
    Gynecol Oncol Rep; 2022 Aug; 42():101026. PubMed ID: 35800987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
    Roncolato F; Lindemann K; Willson ML; Martyn J; Mileshkin L
    Cochrane Database Syst Rev; 2019 Oct; 10(10):CD012160. PubMed ID: 31588998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis.
    Mevius A; Karl F; Wacker M; Welte R; Krenzer S; Link T; Maywald U; Wilke T
    J Cancer Res Clin Oncol; 2023 May; 149(5):1929-1939. PubMed ID: 35840862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
    Tuninetti V; Pace L; Ghisoni E; Quarà V; Arezzo F; Palicelli A; Mandato VD; Geuna E; Cormio G; Biglia N; Borsotti L; Gallo S; Ferrero A; Jacomuzzi E; Fuso L; Pezua Sanjinez JOS; Puppo A; Caglio A; Rognone C; Turinetto M; Scotto G; Di Maio M; Valabrega G
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States.
    Kobayashi M; Garside J; Nguyen J
    J Health Econ Outcomes Res; 2023; 10(2):104-110. PubMed ID: 37954059
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe.
    Zhang J; Kelkar SS; Prabhu VS; Ogando YM; Verma RP; Grall V; Marth C
    Future Oncol; 2024; 20(34):2637-2645. PubMed ID: 39119643
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe.
    Zhang J; Kelkar SS; Prabhu VS; Qiao Y; Grall V; Miles N; Marth C
    BMJ Open; 2024 Apr; 14(4):e079447. PubMed ID: 38569701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer.
    Amonkar MM; Chase M; Myer NM; Wang T; Turzhitsky V; Spira A
    Cancer Treat Res Commun; 2023; 36():100712. PubMed ID: 37301728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England.
    Goulden S; Heffernan K; Sen Nikitas F; Shukla U; Knott C; Hunger M; Pahwa A; Schade R
    Int J Gynecol Cancer; 2023 Nov; 33(11):1715-1723. PubMed ID: 37620100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
    Colomba E; Alexandre J; Le Teuff G; Genestie C; Coupez D; Coquard IR; Brachet PE; de Percin S; Sajous C; Fabbro M; Delanoy N; Joly F; Frenel JS; Pautier P; Leary A
    Gynecol Oncol; 2023 Feb; 169():78-84. PubMed ID: 36521352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer".
    Gadducci A; Cosio S
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
    J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.